AMAG-423

digoxin immune Fab · AMAG Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AMAG-423, covering 2022-04-04 to 2022-04-04. Get the full timeline:

Most recent: Clinical Trial Update: Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia [Phase 2, Phase 3]

See pricing